Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-03-15
2011-03-15
Kosack, Joseph R (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S573000, C549S079000, C562S503000
Reexamination Certificate
active
07906552
ABSTRACT:
A compound comprisingor a pharmaceutically acceptable salt or a prodrug thereof, having the groups described in detail herein is disclosed.Also disclosed herein are compounds comprisingor derivatives thereof, or pharmaceutically acceptable salts, tetrazoles, or prodrugs of compounds of the structure or derivatives thereof, said derivatives being described in detail herein.Also disclosed herein are methods of treating diseases or conditions, including glaucoma and elevated intraocular pressure. Compositions and methods of manufacturing medicaments related thereto are also disclosed.
REFERENCES:
patent: 4055602 (1977-10-01), Nelson
patent: 4119727 (1978-10-01), Buendia et al.
patent: 4141914 (1979-02-01), Grudzinskas et al.
patent: 4166452 (1979-09-01), Generales, Jr.
patent: 4256108 (1981-03-01), Theeuwes
patent: 4265874 (1981-05-01), Bonsen et al.
patent: 4994274 (1991-02-01), Chan et al.
patent: 5028624 (1991-07-01), Chan et al.
patent: 5034413 (1991-07-01), Chan et al.
patent: 5446041 (1995-08-01), Chan et al.
patent: 5599838 (1997-02-01), Sato et al.
patent: 5741810 (1998-04-01), Burk
patent: 5834498 (1998-11-01), Burk
patent: 5972991 (1999-10-01), Burk
patent: 6124344 (2000-09-01), Burk
patent: 6248773 (2001-06-01), Burk
patent: 6376533 (2002-04-01), Burk et al.
patent: 6448290 (2002-09-01), Ohuchida et al.
patent: 6586462 (2003-07-01), Burk et al.
patent: 6649657 (2003-11-01), Cameron et al.
patent: 6680337 (2004-01-01), Burk
patent: 2002/0094981 (2002-07-01), Ponticello et al.
patent: 2523676 (1976-12-01), None
patent: 2626888 (1977-04-01), None
patent: 27 19 244 (1977-11-01), None
patent: 2616304 (1977-11-01), None
patent: 2719244 (1977-11-01), None
patent: 53135955 (1978-11-01), None
patent: WO 99/25358 (1999-05-01), None
patent: WO 02/100388 (2002-12-01), None
patent: WO 03/002755 (2003-01-01), None
Patani et al. “Bioisosterism: A Rational Approach in Drug Design” Chem Rev, 1996, vol. 96, pp. 3147-3176.
Grudzinskas et al. “Prostaglandins and Congeners IV. The Synthesis of Certain 11-Substituted Derivatives of 11-Deoxyprostaglandin E2 and F2a From 15-O-Acetylprostaglandin A2 Methyl Ester” Tetrahedron Letters, 1973, pp. 141-144.
Bito, L.Z.Biological Protection with Prostaglandins, Cohen, M.M., ed., Boca Raton, Fla, CRC Press Inc., 1985, pp. 231-252.
Bito, L.Z.,Applied Pharmacology in the Medical Treatment of GlaucomasDrance, S.M. and Neufeld, A.H. eds., New York, Grune & Stratton, 1984, pp. 477-505.
Bito, L.Z.,Arch. Ophthalmol. 105, 1036 (1987).
Francis A. Carey, Organic Chemistry, New York: McGraw-Hill Book Company 1987, p. 63.
Nilsson et. al.,Invest. Ophthalmol. Vis. Sci. (suppl), 284 (1987).
Siebold et al.,Esterified Prostaglandin Shows ‘Potent’ Promise, Ocular Surgery News, vol. 1, No. 3 (Feb. 1989); pp. 3, 59.
Bartmann, et al., “Luteolytic Prostaglandins Sysnthesis and bilogical Activity,” Feb. 1979, vol. 27, No. 2, pp. 301.
Office Action in U.S. Appl. No. 10/915,987 Date Mailed Jan. 11, 2006.
Notice of Allowance in U.S. Appl. No. 10/915,987 Date Mailed May 2, 2006.
Notice of Allowance in U.S. Appl. No. 10/915,933 Date Mailed Nov. 1, 2006.
Burk Robert M.
Donde Yariv
Garst Michael E.
Allergan Inc.
Ene Doina G.
Forrestal Kevin J.
Kosack Joseph R
Wurst John E.
LandOfFree
Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2705415